CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly ...

Announcement coincides with National Brain Cancer Awareness Day - October 24, and International Brain Tumour Awareness Week - ...

A recent paper published in ScienceAdvances presents a novel deep learning approach to identify computational histopathological signatures that predict overall survival in high-grade gliomas (HGG)—a ...

A glioma is a type of tumor that originates in the central nervous system, specifically in the brain or spinal cord. These tumors originate in glial cells, supportive cells in the brain which serve to ...

Background This case series describes the safety and efficacy of superselective intra-arterial (IA) cerebral infusion of teniposide for the treatment of patients with glioma, to provide new ideas and ...

Definitive diagnosis of glioma requires a biopsy and pathology, including histology and molecular testing. A tissue biopsy ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted ...

Diffuse midline glioma (DMG) is a highly aggressive and fatal pediatric high-grade glioma that primarily affects critical regions of the central nervous system, such as the pons, thalamus ...

Methods Adult patients with a new histopathological diagnosis of high-grade glioma, who underwent radiotherapy, participated in a semistructured, face-to-face interview. Different segments of the ...

Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver ...

Patients with LGG were divided into high risk and low risk groups according to the median risk score ... (GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas; CGGA, The China Glioma Genome ...